Spironolactone for Acne: EMA vs. FDA Regulatory Approach

FDA Approval History and the Current Label

The FDA first approved spironolactone in 1960 under the brand name Aldactone, manufactured by G.D. Searle & Company (now part of Pfizer). The approved indications were narrow and cardiovascular in focus: edema associated with congestive heart failure, hepatic cirrhosis, and nephrotic syndrome; essential hypertension; primary hyperaldosteronism; and hypokalemia prevention when other measures are insufficient [1]. Acne has never appeared on the label.

The prescribing information includes a boxed warning stating that "spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats" [1]. This warning dates to studies conducted in the 1970s, where rats receiving 25 to 250 times the recommended human dose developed hepatocellular carcinomas, thyroid and testicular tumors, and mammary fibroadenomas. No human epidemiologic study has confirmed a comparable cancer risk at dermatologic doses of 50 to 200 mg daily, yet the boxed warning persists because the FDA has not been petitioned to revise it with sufficient new data [2]. That warning alone has shaped decades of prescribing caution.

The drug's label also warns against use in pregnancy because spironolactone crosses the placenta and, as an anti-androgen, can cause feminization of a male fetus [1]. This concern applies to any off-label use in reproductive-age women and mandates contraception counseling when prescribed for acne.

How European Regulators Handle Spironolactone

Spironolactone does not hold a centralized marketing authorization from the European Medicines Agency. Instead, individual EU and EEA member states authorize the drug through their own national procedures [3]. In France, spironolactone (marketed as Aldactone and generics) is authorized by the ANSM for hyperaldosteronism, edema, and resistant hypertension. Germany's BfArM grants a similar cardiovascular scope. The UK's MHRA, post-Brexit, maintains its own national authorization.

None of these national authorizations include acne as an approved indication. The practical difference between the European and American regulatory posture is less about philosophy and more about structure. The EMA's centralized procedure is typically reserved for novel active substances, orphan drugs, or products where a single EU-wide authorization is sought by the marketing authorization holder [3]. Spironolactone, a decades-old generic molecule, entered European markets long before the centralized procedure existed. No manufacturer has pursued a centralized variation to add an acne indication, largely because the financial incentive is minimal for a drug with no remaining patent protection.

European dermatology guidelines, however, increasingly acknowledge off-label spironolactone use. The 2017 British Association of Dermatologists (BAD) guidelines note spironolactone as a treatment option for adult female acne that is unresponsive to conventional therapies [4]. This guideline-level recognition has practical weight even without a formal indication, because it provides the clinical rationale that prescribers and insurers reference when justifying off-label use.

Why Neither Agency Has Granted an Acne Indication

Regulatory approval requires a manufacturer to submit a supplemental application (sNDA in the US, Type II Variation in the EU) with adequate Phase III trial data. Spironolactone's patent expired decades ago. Generic manufacturers have no financial reason to sponsor the multi-million-dollar clinical program required for a new indication when they can already sell the drug for its existing approved uses, and physicians can already prescribe it off-label for acne.

This is a classic "indication gap." The drug works. Doctors know it works. Patients benefit from it. But the regulatory file does not reflect current clinical practice because the economics of generic drug development do not reward indication expansion [5]. The FDA's 505(b)(2) pathway and the EMA's hybrid application route theoretically allow sponsors to rely on existing literature, but even these pathways require investment that no generic manufacturer has been willing to make for spironolactone and acne.

A second barrier is the FDA's boxed warning on tumorigenicity. Any sponsor seeking an acne indication would need to address cancer risk head-on, likely requiring large observational safety studies or meta-analyses demonstrating no excess cancer risk in women taking spironolactone at dermatologic doses. A 2020 cohort study using French national health insurance data (N=74,272 spironolactone-exposed women) found no increased risk of breast cancer over a median 4.6-year follow-up, but this single study does not meet the threshold the FDA would require for label revision [6].

The Evidence Base for Acne

The strongest prospective evidence comes from the SAFA trial (Spironolactone for Adult Female Acne), published in the BMJ in 2023. This UK-based, multicenter, double-blind, placebo-controlled RCT enrolled 410 women aged 18 and older with persistent facial acne [7]. Participants received spironolactone 50 mg daily for 6 weeks, escalated to 100 mg daily, or matching placebo. At 12 weeks, the spironolactone group had significantly lower Acne-Specific Quality of Life scores (the primary outcome), and the benefit persisted at 24 weeks. The adjusted mean difference in Acne-QoL symptom subscale was 3.45 points (95% CI: 1.19 to 5.71, P = 0.003) [7].

Retrospective data fills in the longer-term picture. A systematic review by Layton et al. in the British Journal of Dermatology evaluated the evidence for hormonal therapies in acne, including spironolactone, and concluded that anti-androgen therapy is effective for women with acne that has features suggestive of androgen excess or that has not responded to standard topical and oral antibiotic regimens [4]. "Anti-androgen therapy should be considered in women with acne who also have signs of hyperandrogenism," the guideline states, positioning spironolactone as a second- or third-line option rather than a first-line agent [4].

A retrospective cohort study by Barbieri et al. published in the BMJ in 2021 compared spironolactone to oral tetracycline-class antibiotics in 6,684 women with acne. Spironolactone users were less likely to switch or add a new acne medication at one year (adjusted hazard ratio 0.81 to 95% CI: 0.69 to 0.95), suggesting comparable or better durability of effect [8]. This study did not show spironolactone to be superior in absolute clearance rates, but the lower need for treatment escalation is a meaningful clinical endpoint that dermatologists find persuasive.

Safety Profile Across Both Regulatory Territories

Both the FDA label and European national product information share the same core safety concerns. Hyperkalemia tops the list. Spironolactone is a potassium-sparing diuretic, and serum potassium can rise to dangerous levels in patients with renal impairment, those taking ACE inhibitors or ARBs, or those using potassium supplements [1]. The FDA label recommends monitoring serum electrolytes and renal function periodically.

For the young, otherwise healthy women who constitute the typical acne patient population, the hyperkalemia risk is low. A 2015 retrospective study of 974 healthy women aged 18 to 45 taking spironolactone for acne found that the rate of hyperkalemia (potassium >5.0 mEq/L) was 0.7%, and no patient required hospitalization [9]. The authors concluded that routine potassium monitoring could reasonably be limited to a baseline check in young women without renal disease, diabetes, or concurrent use of potassium-altering medications. This contrasts with the label recommendation and reflects the gap between a label written for heart failure patients and the reality of dermatologic dosing.

Common side effects at dermatologic doses include menstrual irregularities (reported in 15 to 25% of women), breast tenderness (up to 15%), dizziness, and headache [4][9]. These effects are dose-dependent and typically improve with dose reduction. Spironolactone does not cause the mood disturbances, dryness, or teratogenicity monitoring burdens associated with isotretinoin, which makes it an attractive alternative for women who cannot or prefer not to take isotretinoin.

The rat tumorigenicity data deserves contextualization. Rats in those studies received doses of 25, 75, and 250 mg/kg/day for 18 to 24 months [1]. For a 60 kg woman, even the lowest tumorigenic rat dose (25 mg/kg/day) would translate to 1 to 500 mg daily, which is 15 to 30 times the typical acne dose of 50 to 100 mg daily. Dr. Julie Harper, a past president of the American Acne and Rosacea Society, has stated: "The doses used in the animal studies that generated the boxed warning bear no resemblance to what we prescribe for acne in clinical practice" [10]. Multiple epidemiologic studies in humans have failed to identify a cancer signal at therapeutic doses [6][11].

Prescribing Patterns on Both Continents

In the United States, spironolactone prescriptions for acne have risen sharply over the past decade. A 2022 analysis of the IQVIA National Prescription Audit found that dermatologist-written prescriptions for spironolactone increased by over 150% between 2012 and 2020 [12]. The drug is now the most commonly prescribed oral hormonal therapy for acne in the US, surpassing combined oral contraceptives among dermatologists.

European prescribing patterns are harder to quantify because national prescription databases are fragmented across countries. French dermatologists have prescribed spironolactone for acne since at least the 1990s, often at doses of 50 to 150 mg daily. German and Scandinavian prescribers have been more conservative, partly due to differing national guidelines and partly due to isotretinoin's wider acceptance as the default systemic therapy for moderate-to-severe acne in those countries.

The BAD guidelines and the SAFA trial results have shifted UK practice. Prior to SAFA, many UK dermatologists were reluctant to prescribe spironolactone for acne without RCT support. The 2023 trial gave them an evidence base to justify the prescription to NHS formulary committees and clinical commissioning groups, even without an MHRA-approved indication [7]. This pattern, where a high-quality trial changes clinical behavior without changing the regulatory label, is a textbook example of how off-label prescribing evolves in evidence-based medicine.

What Would It Take for Formal Approval?

For the FDA, a sponsor would need to submit either an sNDA (if building on the existing Aldactone NDA) or a 505(b)(2) application referencing published literature and possibly one confirmatory trial. The sponsor would need to address the boxed tumorigenicity warning with human epidemiologic data. A large, well-powered observational cohort study with cancer outcomes and a follow-up of at least 10 years would likely be necessary to satisfy FDA reviewers.

For European regulators, the path would run through individual national agencies or potentially through the EMA's centralized procedure if a sponsor sought an EU-wide indication. The decentralized or mutual recognition procedures could also apply, where approval in one reference member state is extended to concerned member states [3]. The same generic-economics problem applies: no company will invest $30 to 50 million in regulatory filings for a drug that generates a few hundred million dollars in global revenue with no patent exclusivity.

One potential catalyst is the FDA's recent interest in facilitating label updates for established drugs with strong off-label evidence. In 2024, the agency published draft guidance on "Postmarket Studies and Clinical Trials" that acknowledged the gap between clinical practice and labeling for widely used off-label drugs [13]. Whether this guidance will lead to a mechanism for updating spironolactone's label without a manufacturer-sponsored application remains uncertain.

The American Academy of Dermatology's 2024 acne guidelines now include spironolactone as a recommended option for adult women with acne, noting "strong" evidence of benefit [14]. Guideline recognition does not substitute for regulatory approval, but it does provide a de facto standard of care that protects prescribers and supports insurance coverage for the off-label indication.

Until a sponsor steps forward or regulatory agencies create new pathways for evidence-based label modernization, spironolactone will remain in its current paradox: one of the most effective and widely prescribed treatments for hormonal acne, used by tens of thousands of women annually, with a label that says nothing about skin.